← Back to all trials
Completed
NCT02847052
Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease
Conditions: Inflammatory Bowel Disease
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 52
Sponsor: Nantes University Hospital
Location: CHU de Nantes Nantes
Summary
IL-22 is an IL-10 family cytokine that plays major actions to increase intestinal epithelial barrier function and regeneration during experimental colitis. IL-22 binding protein is a small, soluble, and secreted protein potently inhibiting IL-22 actions through preventing the binding with IL-22 Recepteur. This study aims at characterizing how IL-22 binding protein is regulated in Inflammatory bowel disease to better understand the way IL-22 acts on epithelial cells during flares of the disease.
Eligibility Criteria
Inclusion criteria
1. Crohn's disease or Ulcerative colitis
2. Healthy controls paired for age and sex
3. Samples availability in the biobank
4. Signed consent
5. No (Immune Mediated Inflammatory Disorders other than Inflammatory bowel disease
6. No other conditions predicted or known to affect IL-22/IL-22 recepteur /IL-22 binding protein regulation
7. Availability of clinical data
8. Age \>18 y.o.
9. No pregnancy
Source: ClinicalTrials.gov (NCT02847052). StuddyBuddy aggregates publicly available trial information.
